Atlas Trials

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Clinical trial NCT00316953 · COMPLETED

Trial details

NCT number
NCT00316953
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveMeningeal Chronic Myelogenous LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRelapsing Chronic Myelogenous LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
Start date
2006-03-01
Primary completion
2009-09-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.